Incyte (NAS:INCY) Change In Inventory

: $-68 Mil (TTM As of Dec. 2022)

View and export this data going back to 1993. Start your Free Trial

Incyte's change in inventory for the quarter that ended in Dec. 2022 was $-19 Mil. It means Incyte's inventory increased by $19 Mil from Sep. 2022 to Dec. 2022 .

Incyte's change in inventory for the fiscal year that ended in Dec. 2022 was $-68 Mil. It means Incyte's inventory increased by $68 Mil from Dec. 2021 to Dec. 2022 .

Incyte's Total Inventories for the quarter that ended in Dec. 2022 was $42 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Incyte's Days Inventory for the quarter that ended in Dec. 2022 was 67.72.

Inventory Turnover measures how fast the company turns over its inventory within a year. Incyte's Inventory Turnover for the quarter that ended in Dec. 2022 was 1.35.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Incyte's Inventory-to-Revenue for the quarter that ended in Dec. 2022 was 0.05.

Incyte Change In Inventory Historical Data

The historical data trend for Incyte's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Inventory

4.04

-6.10

-19.47

-20.97

-67.50

Incyte Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Change In Inventory																-4.75	-13.90	-23.29	-11.13	-19.19

Incyte Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-68 Mil.

Incyte (NAS:INCY) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Incyte's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	43.932	/	59.2	*	365 / 4
	=	67.72

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Incyte's Inventory Turnover for the quarter that ended in Dec. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	59.2	/	43.932
	=	1.35

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Incyte's Inventory to Revenue for the quarter that ended in Dec. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	43.932	/	926.7
	=	0.05

Incyte Change In Inventory Related Terms

Thank you for viewing the detailed overview of Incyte's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (NAS:INCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (NAS:INCY) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Executives

Susanne Schaffert	director	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Thomas Tray	officer: Principal Accounting Officer	C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Katherine A High	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Edmund Harrigan	director
Michael James Morrissey	officer: EVP, Head of Tech. Operations	IN CARE OF INCYTE CORPORATION, 1801 AUGUSTINE CUT OFF, WILMINGTON DE 19803
Jonathan Elliott Dickinson	officer: EVP, General Manager, Europe	CARE OF INCYTE CORPORATION, 1801 AUGUSTINE CUT OFF, WILMINGTON DE 19803
Christiana Stamoulis	officer: EVP & Chief Financial Officer	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Dashyant Dhanak	officer: EVP & Chief Scientific Officer	C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Maria E Pasquale	officer: EVP & General Counsel	C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Jacqualyn A Fouse	director	C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Vijay K Iyengar	officer: EVP GPS, BD, & Licensing	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Steven H Stein	officer: EVP & Chief Medical Officer	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Paul Trower	officer: VP, Finance & Prin Acc Officer	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Paul J Clancy	director	C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142